featured
Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Respir Med 2022 Jun 07;[EPub Ahead of Print], H Montgomery, FDR Hobbs, F Padilla, D Arbetter, A Templeton, S Seegobin, K Kim, JAS Campos, RH Arends, BH Brodek, D Brooks, P Garbes, J Jimenez, GCKW Koh, KW Padilla, K Streicher, RM Viani, V Alagappan, MN Pangalos, MT EsserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.